Latest Conference Articles

Prophylactic Letermovir Limits CMV Infections Post-Transplantation

Prophylactic treatment with letermovir lowered the rates of cytomegalovirus infection and all-cause mortality compared with placebo for CMV-seropositive patients following an allogeneic hematopoietic stem cell transplant.

Vorinostat Lowers Acute GVHD in Patients Receiving Unrelated Donor HSCT

Vorinostat combined with tacrolimus and methotrexate represents a potentially effective combination to mitigate graft-versus-host disease in the setting of matched unrelated donor myeloablative conditioning hematopoietic stem cell transplant.

Dr. Marty on Letermovir for CMV Prevention After Stem Cell Transplant

Francisco Marty, MD, Dana-Farber Cancer Institute, discusses the initial results of the Phase III trial evaluating letermovir for CMV after bone marrow transplant.

Nursing Coordination Invaluable to Successful Delivery of CAR T Therapy

Proper care coordination and patient education are essential to the success of delivering chimeric antigen receptor T-cell therapy, particularly in preparing patients for potential adverse events.

New and Emerging Approaches Target the Immunologic Chaos of GVHD

A host of new and emerging therapies for acute and chronic graft-versus-host disease are on the horizon and include B-cell depletion, IL-2, inhibitors of JAK1/JAK2, extracorporeal photopheresis, and the BTK inhibitor ibrutinib.

Novel Pretransplant Conditioning Regimens Seek to Reduce Relapse in Blood Cancers

Sergio A. Giralt, MD, reviewed emerging strategies to improve stem cell transplantation outcomes by reducing the risk of relapse using novel drugs and targeted radiotherapy.

Dr. Locke on the ZUMA-1 Trial of KTE-C19 for Lymphoma

Fred Locke, MD, Moffitt Cancer Center discusses the interim results of the ZUMA-I trial of Kte-C19, a CAR T-cell therapy.

Dr. Scott on Conditioning Regimens for Stem Cell Transplants

Bart Scott, MD, Fred Hutchinson Cancer Research Center, explains the importance of the intensity of conditioning for stem cell transplants.

Robert Korngold on Advances in Bone Marrow Transplant

Robert Korngold, PhD, John Theurer Cancer Center looks back on the advances we've made so far in bone marrow transplant.

Vaccine Limits Herpes Zoster Infections Following Stem Cell Transplant

Treatment with an inactivated varicella zoster virus vaccine, known as V212, lowered the cumulative incidence rate of herpes zoster infection and complications for patients undergoing autologous hematopoietic stem cell transplantation.

Outcomes Have Improved Over Time in Myeloma Patients Relapsing Early After ASCT

Rates of early relapse post-autologous stem cell transplant in patients with relapsing multiple myeloma have not changed over time, but post-relapse survival among early relapsers has improved for patients transplanted after 2005 and for those relapsing since 2008.

Dr. Lancet on CPX-351 Compared to Chemotherapy for Older Adults With AML

Dr. Lancet of Moffitt Cancer Center explains the use of CPX-351 treatment compared to induction chemotherapy, for older adult patients with acute myeloid leukemia.

Dr. Kebriaei on the Iomab-B Clinical Trial

Partow Kebriaei, MD, discusses the Iomab-B clinical trial for older patients with acute myeloid leukemia.

Carfilzomib Maintenance Improves Response Following Transplant in Relapsed Multiple Myeloma

According to data from a phase I/II clinical trial, carfilzomib can be safely combined with melphalan in a conditioning regimen prior to autologous hematopoietic cell transplantation in patients with relapsed multiple myeloma.

CPX-351 Offers Potential Bridge to Transplant for Secondary AML

More patients with acute myeloid leukemia could proceed to transplant following treatment with CPX-351 compared with the traditional 7+3 chemotherapy regimen.

Vogelzang Emphasizes Aggressive Biopsies, Novel Therapies in Urothelial Carcinoma

At the 2017 Genitourinary Cancers Symposium, Nicholas J. Vogelzang, MD, discussed diagnostic practices and emerging therapies in the field of bladder cancer.

Cabozantinib Regimens Active Across Multiple Advanced GU Malignancies

The combination of cabozantinib and nivolumab, with or without ipilimumab, proved safe and active in advanced genitourinary cancers, particularly urothelial cancer.

Combination Makes First-Line Case for Metastatic PD-L1+ RCC

Patients with PD-L1-positive metastatic renal cell carcinoma had a reduction in the risk of progression or death when treated in frontline with the combination of atezolizumab and bevacizumab instead of sunitinib, according to results of a randomized trial.

Dr. Saad on Recent Updates in Active Surveillance in Prostate Cancer

Fred Saad, MD, professor and chairman of Urology, director of Genitourinary Oncology, the University of Montreal Hospital Centers, discusses recent updates in active surveillance for patients with prostate cancer.

Dr. Powles on Durvalumab in Urothelial Cancer

Thomas Powles, MD, Barts Cancer Institute, discusses durvalumab as a second-line therapy in locally advanced and metastatic urothelial cancer.

Ipilimumab Broadens Nivolumab Activity in Urothelial Cancer

Five of 8 patients with metastatic urothelial cancer benefited from the combination of ipilimumab and nivolumab after having no response to single-agent nivolumab.

Pembrolizumab Plus Chemo Shows Promise in Urothelial Carcinoma

Combining the PD-1 inhibitor pembrolizumab with chemotherapy induced objective responses in one-third of patients with previously treated metastatic urothelial carcinoma.

Dr. Jonasch on Promise of Immuno-Oncology Agents in RCC

Eric Jonasch, MD, professor, The University of Texas MD Anderson Cancer Center, discusses the promise of immuno-oncology agents in sarcomatoid renal cell carinoma (RCC).

Dr. Steinberg on Trial of HS-410 Vaccine in Bladder Cancer

Gary Steinberg, MD, director, Urologic Oncology, The University of Chicago Medicine, discusses the immune response results of vesigenurtacel-I (HS-410) vaccine in non-muscle invasive bladder cancer (NMIBC).

Dr. Morris on Bone Biomarkers for Radium-223 in Prostate Cancer

Michael J. Morris, MD, Memorial Sloan Kettering Cancer Center, discusses bone biomarkers for radium-223 dichloride (Xofigo) in castration-resistant prostate cancer.

Durvalumab Impresses in Advanced Urothelial Cancer

The PD-L1 inhibitor durvalumab demonstrated compelling clinical activity and a manageable safety profile as second-line therapy for locally advanced or metastatic urothelial cancer.

Genomic Test Predicts Metastasis, Mortality in Prostate Cancer

The genomic-based Decipher test effectively predicted metastasis and prostate cancer-specific mortality from diagnostic biopsy specimens for patients with intermediate- and high-risk prostate cancer.

Dr. Balar on Results of KEYNOTE-052 in Urothelial Cancer

Arjun Balar, MD, director, Genitourinary Medical Oncology Progam, NYU Langone Medical Center, discusses the results from the KEYNOTE-053 trial in cisplatin-ineligible advanced urothelial carcinoma.

Olaparib, Durvalumab Combo Active in Prostate Cancer

According to preliminary results from an ongoing trial, half of a small group of patients with metastatic castration-resistant prostate cancer had a PSA response during treatment with the PD-L1 inhibitor durvalumab and the PARP inhibitor olaparib (Lynparza).

AR-FL mRNA Correlates With Response to AR-Targeted Therapies

According to results of a prospective clinical study, circulating tumor cell mRNA of full-length androgen receptor (AR) correlated with detection of the AR-V7 variant and with response to AR-targeted therapy for castration-resistant prostate cancer.